Increased risk of hospitalisation for COVID-19 patients infected with SARS-CoV-2 variant B.1.1.7

Tommy Nyberg, research associate ^{a*} Katherine A. Twohig, senior epidemiology scientist ^b Ross J. Harris, senior statistician ^c Shaun R. Seaman, senior research associate ^a Joe Flannagan, senior epidemiology scientist ^b Hester Allen, principal epidemiology scientist ^b Andre Charlett, head of department ^c Daniela De Angelis, professor of statistical science for health ^{a,c} Gavin Dabrera, consultant in public health medicine ^b Anne M. Presanis, senior investigator statistician ^a

^a MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.

^b COVID-19 National Epidemiology Cell, Public Health England, London, United Kingdom.

^c National Infection Service, Public Health England, London, United Kingdom.

* Corresponding author: tommy.nyberg@mrc-bsu.cam.ac.uk

Abstract

Objective To evaluate the association between coronavirus disease 2019 (COVID-19) diagnosis with SARS-CoV-2 variant B.1.1.7 (also known as Variant of Concern 202012/01) and the risk of hospitalisation compared to diagnosis with wildtype SARS-CoV-2 variants.

Design Retrospective cohort, analysed using a matched nested case-control study design.

Setting Community-based SARS-CoV-2 testing in England, individually linked with hospitalisation data from the Secondary Uses Service and the Emergency Care Data Set.

Participants 493,053 laboratory-confirmed COVID-19 patients, of whom 19,482 had been hospitalised, tested between 23 November 2020 and 4 January 2021 and analysed at a laboratory with an available TaqPath assay that enables assessment of S-gene target failure (SGTF). SGTF is a proxy test for the B.1.1.7 variant. Nested case-control analysis of 18,814 pairs of hospitalised/non-hospitalised patients, one-to-one matched on age, sex, ethnicity, deprivation, region of residence, and date of positive test (matches found for 96.6%).

Main outcome measures Hospitalisation between 1 and 14 days after the first positive SARS-CoV-2 test.

Results The matching-adjusted conditional odds ratio of hospitalisation was 1.58 (95% confidence interval 1.50 to 1.67) for COVID-19 patients infected with a SGTF-associated variant, compared to those infected with non-SGTF-associated variants. Secondary cohort analyses yielded similar estimates. The effect was modified by age (p<0.001), with ORs of 0.96—1.13 below age 20 years and 1.57—1.67 in age groups 40 years or older.

Conclusions The results suggest that the risk of hospitalisation is higher for individuals infected with the B.1.1.7 variant compared to wildtype SARS-CoV-2, likely reflecting a more severe disease. The higher severity may be specific to older age groups.

What is already known on this topic

- The SARS-CoV-2 B.1.1.7 variant was discovered in England in December 2020 and has now become the dominant lineage in the country, owing to a higher transmissibility than wildtype SARS-CoV-2.
- Some evidence suggests that B.1.1.7 is associated with more severe disease, but the studies that have found an association with increased mortality have been limited by a lack of data on confounding due to increased hospital burden.
- Hospitalisation as a measurement of disease severity is less likely to be positively confounded by hospital burden.

What this study adds

- Based on linkage of nationwide community SARS-CoV-2 testing data with routine hospital admission records, we found that COVID-19 patients who tested positive for the B.1.1.7 variant had a 1.58-fold odds of hospitalisation (95% confidence interval 1.50 to 1.67) compared to COVID-19 patients with wildtype variants.
- The results likely reflect a more severe disease associated with the SARS-CoV-2 B.1.1.7 variant, particularly in older age groups.

1. Background

Since its discovery in England in December 2020, the SARS-CoV-2 B.1.1.7 variant has been reported in 114 countries globally [1]. In England, the prevalence of B.1.1.7 rapidly increased and it has now become the predominant SARS-CoV-2 lineage [2], prompting the re-implementation of social and physical distancing measures to control infection rates. These measures included closures of schools, non-essential retail and hospitality outlets and stay at home orders [3].

Initial concerns around B.1.1.7 emerged from analyses which determined a higher transmissibility [2,4,5]. On 18th December 2020, the variant was re-designated as a Variant of Concern (VOC-202012/01) and subsequent studies have found B.1.1.7 to be associated with higher mortality than other SARS-CoV-2 variants [6–8].

The burden of COVID-19 on hospital services is a key measure outlined by the UK government on progress in controlling the pandemic, influencing decisions on how quickly social and physical distancing measures can be removed. As B.1.1.7 is now the predominant SARS-CoV-2 lineage in England, any potential increased likelihood of hospitalisation with this variant will impact the national healthcare burden and decisions on lifting restrictions.

Initial assessments of hospitalisation were based on ecological analyses, looking at distribution of variant cases in comparison to the levels of healthcare demand at different geographies [5,9,10]. One study, based on whole genome sequencing, has reported on the risk of hospitalisation using individual-level follow-up of COVID-19 patients with B.1.1.7 compared to wildtype SARS-CoV-2 [11]. However, that study was limited by a moderate sample size due to operational constraints of sequencing, leading to wide confidence intervals for the risk estimates. Hospitalisations linked to individual variant cases based on routine testing data in England, which provide a larger sample size, have not yet been analysed, leaving a gap in the available evidence.

The B.1.1.7 genetic profile includes a deletion of six nucleotides in the S-gene and has been associated with target failures for this gene in PCR testing using a three-gene assay (ORF1ab, N gene and S-gene). While other mutations can also cause an S-gene target failure (SGTF), more than 90% of sequenced SGTF samples since the week commencing 23 November 2020 were confirmed as matching the B.1.1.7 profile [2]. Therefore, SGTF provides an indicator from routine PCR testing that can be used as a proxy for B.1.1.7 and that is more rapidly and widely available than sequencing results.

The aim of this study was to assess the association with hospitalisation for COVID-19 patients infected with SGTF-associated variants compared to COVID-19 patients with non-SGTF variants.

2. Methods

2.1 Identification of confirmed COVID-19 patients by SGTF status

Lighthouse laboratories undertake large-scale PCR testing of respiratory specimens for SARS-CoV-2 infection in the United Kingdom, predominantly for community-originated testing. These laboratories may receive specimens from testing nationwide depending on demand, and so individual laboratories do not have a fixed geographical coverage. Confirmed COVID-19 patients with SGTF were identified from results uploaded to the Second Generation Surveillance System (SGSS)

from the three Lighthouse laboratories using TaqPath assays (Milton Keynes, Alderley Park and Glasgow Lighthouse Laboratories). The identification of these records relied on cycle threshold (CT) values being reported into SGSS from these three laboratories.

We included COVID-19 patients with a positive PCR test from the Pillar 2 community testing programme between 23rd November 2020 and 4th January 2021 and whose specimen had been analysed in one of the TaqPath assay Lighthouse laboratories. Tests from the Pillar 1 programme [12] were not analysed at Lighthouse laboratories and hence have not routinely been assessed for SGTF status. SGTF patients were defined as those patients who had CT values that met the definition for SGTF (ORF1ab and N-gene targets with CT values ≤30 and no values detected for the S-gene). Non-SGTF patients were defined as those patients who had CT values ≤30 at all targets (ORF1ab, N-gene and S-gene).

Laboratory data for all included patients were extracted from SGSS and included information on age, sex, ethnicity, area of residence, index of multiple deprivation (IMD).

2.2 Assessment of hospitalisation

All patients were linked to the Secondary Uses Service (SUS) [13] dataset and the Emergency Care Data Set (ECDS) [14] to obtain information on hospital admissions, as previously described [15]. SUS is an administrative dataset which includes healthcare and hospitalisation data for completed admissions and treatments submitted to NHS Digital. SUS data is not reported until a hospital admission episode is complete (i.e. transfer, discharge or death); ongoing hospitalisations are not included in this dataset. This information can be complemented with ECDS, a similar administrative dataset recording attendances at Emergency Departments, including hospital admissions following emergency room attendance, thus providing another route to capture hospitalisation earlier than in SUS.

SUS/ECDS data were extracted and linked with the laboratory data, including hospitalisation records up to the 13th March 2021. If a COVID-19 patient was detected in SUS, they were classified as hospitalised with COVID-19 if they entered the hospital between 1 and 14 days following their specimen date. If the individual was detected in ECDS only, they were classified as hospitalised if they had a discharge status of "Admitted" or "Transferred" and their attendance date was between 1 and 14 days following their specimen date. Individuals who tested positive on or after their hospital admission were excluded to avoid bias of healthcare-acquired SARS-CoV-2 infections or testing at admission for non-COVID-19-related hospitalisation. Similarly, individuals in hospital within 6 weeks prior to testing positive were excluded from analysis, due to the possibility of hospital-acquired infection.

2.3 Patient and public involvement

This study was observational and based on data from routine healthcare records. No patients were directly involved in the study.

2.4 Ethical considerations

This surveillance was performed as part of PHE's responsibility to monitor COVID-19 during the current pandemic. PHE has legal permission, provided by Regulation 3 of The Health Service (Control

of Patient Information) Regulations 2002 to process confidential patient information (http://www.legislation.gov.uk/uksi/2002/1438/regulation/3/made) under Sections 3(i) (a) to (c), 3(i)(d) (i) and (ii) and 3(3) as part of its outbreak response activities. As such this work falls outside the remit for ethical review.

2.5 Statistical analysis

The primary analysis was a matched nested case-control analysis [16]. A nested case-control design has the advantage that it allows the use of assumption-free adjustment methods such as matching when the exposure is common [17], and here the exposure (diagnosis with a SGTF versus a non-SGTF variant) was commoner than the outcome (hospitalisation within 1-14 days after testing positive for SARS-CoV-2). Secondary analyses include a stratified cohort analysis, exploratory cohort analysis and a matched cohort analysis.

We used Stata software (release 14.1, StataCorp LLC, College Station, TX, USA) for the statistical analysis.

2.5.1 Matched nested case-control analysis

We matched, by prespecified covariates (5-year age group, sex, ethnicity, region of residence (PHEC), week of specimen and IMD quintile), one COVID-19 patient who was not hospitalised 14 days after the positive test date ("controls") to each COVID-19 patient who had been hospitalised within 14 days ("cases"). We omitted cases for whom a match was not found. We assessed the association between hospitalisation and SGTF status using conditional logistic regression, stratified by matching sets.

In a secondary analysis, we matched on lower tier local authority (LTLA; >300 areas) of residence instead of PHEC (9 regions).

2.5.2 Stratified cohort analysis

Secondly, we performed a stratified cohort analysis, where we instead used the entire dataset, stratified by the adjustment covariates. This approach permits the number of cases and controls in each stratum to be imbalanced, allowing the use of all strata in which there were at least one case and one control. We assessed the association between hospitalisation and SGTF status using conditional logistic regression, stratified by covariate strata.

2.5.3 Exploratory cohort analysis

We further assessed other associations of interest using exploratory cohort analysis of the combined SGTF and non-SGTF cohorts. The odds of hospitalisation within 1-14 days of testing positive was logistically regressed on the covariates: SGTF, age, sex, ethnicity, PHEC, IMD quantile and week of sample. We considered interactions between SGTF and covariates, which were assessed using likelihood ratio tests.

We also fitted Cox regression models in a time-to-event framework, considering hospitalisation within 14 and 60 days of testing positive. Individuals who died prior to hospitalisation were censored in the main analysis; we assessed the potential impact of mortality as a competing risk using the Fine

and Gray sub-distribution hazard model. The same covariate structure used in the logistic regression model was used.

2.5.4 Matched cohort analysis

Finally, a sensitivity analysis using a matched cohort design to also assess the association between hospitalisation and SGTF status was carried out. SGTF and non-SGTF patients were one-to-one matched by four factors: age group (ten-year age band), sex, week of specimen, and LTLA of residence. Patients for whom a match was not found were excluded.

3. Results

3.1 Description of COVID-19 patients by SGTF status

Within the study period, there were 493,053 confirmed SARS-CoV-2 cases reported from TaqPath assay Lighthouse laboratories with valid SGTF status, and who were not hospitalised within 6 weeks prior to testing positive: 292,064 SGTF patients and 200,989 non-SGTF patients. These patients represented 42.3% of all confirmed cases during that time. Table 1 shows the characteristics of the SGTF and non-SGTF patients. The mean age of SGTF patients was 36.4 years, and in the non-SGTF group the mean age was 37.3 years. There were marked differences by region, with higher proportions of SGTF patients in London, East of England and the South East; and differences over time, with the majority of SGTF patients occurring towards the end of December 2020 and the start of 2021, while non-SGTF patients decreased over time.

| | SGTF | | Non-SGT | F |
|-----------------|---------|---------|---------|---------|
| | Count | Percent | Count | Percent |
| Total | 292,064 | | 200,989 | |
| Age | | | | |
| <10 | 16,194 | 5.5% | 10,400 | 5.2% |
| 10-19 | 36,207 | 12.4% | 26,738 | 13.3% |
| 20-29 | 55,457 | 19.0% | 36,278 | 18.0% |
| 30-39 | 58,113 | 19.9% | 38,782 | 19.3% |
| 40-49 | 52,823 | 18.1% | 34,361 | 17.1% |
| 50-59 | 43,776 | 15.0% | 30,744 | 15.3% |
| 60-69 | 20,087 | 6.9% | 15,102 | 7.5% |
| 70-79 | 7,022 | 2.4% | 5,718 | 2.8% |
| 80+ | 2,385 | 0.8% | 2,866 | 1.4% |
| Sex | | | | |
| Female | 150,541 | 51.5% | 106,306 | 52.9% |
| Male | 141,523 | 48.5% | 94,683 | 47.1% |
| PHEC Region | | | | |
| East Midlands | 6,845 | 2.3% | 18,479 | 9.2% |
| East of England | 42,677 | 14.6% | 11,559 | 5.8% |
| London | 94,811 | 32.5% | 25,674 | 12.8% |
| North East | 10,564 | 3.6% | 16,465 | 8.2% |
| North West | 25,344 | 8.7% | 41,237 | 20.5% |
| South East | 65,853 | 22.6% | 16,336 | 8.1% |

Table 1: Characteristics of SGTF and non-SGTF patients

| South West | 7,384 | 2.5% | 7,566 | 3.8% |
|-----------------------------|---------|-------|---------|-------|
| West Midlands | 28,995 | 9.9% | 35,696 | 17.8% |
| Yorkshire & Humber | 9,268 | 3.2% | 27,744 | 13.8% |
| Ethnicity | | | | |
| White | 210,679 | 72.1% | 147,916 | 73.6% |
| Asian | 42,392 | 14.5% | 33,049 | 16.4% |
| Black | 14,301 | 4.9% | 6,709 | 3.3% |
| Mixed | 7,014 | 2.4% | 3,820 | 1.9% |
| Other | 13,188 | 4.5% | 6,608 | 3.3% |
| Unknown | 4,490 | 1.5% | 2,887 | 1.4% |
| Presence of symptoms | | | | |
| No | 36,803 | 12.6% | 24,590 | 12.2% |
| Yes | 255,261 | 87.4% | 176,399 | 87.8% |
| Index of multiple | | | | |
| deprivation | | | | |
| Quintile 1 – most deprived | 51,462 | 17.6% | 55,113 | 27.5% |
| Quintile 2 | 66,313 | 22.7% | 43,927 | 21.9% |
| Quintile 3 | 60,852 | 20.9% | 36,543 | 18.2% |
| Quintile 4 | 56,461 | 19.4% | 34,685 | 17.3% |
| Quintile 5 – least deprived | 56,653 | 19.4% | 30,488 | 15.2% |
| Specimen date | | | | |
| 23/11/2020 - 01/12/2020 | 10,753 | 3.7% | 49,249 | 24.5% |
| 02/12/2020 - 08/12/2020 | 16,802 | 5.8% | 32,359 | 16.1% |
| 09/12/2020 - 15/12/2020 | 42,036 | 14.4% | 37,001 | 18.4% |
| 16/12/2020 - 22/12/2020 | 49,445 | 16.9% | 27,015 | 13.4% |
| 23/12/2020 - 31/12/2020 | 109,255 | 37.4% | 38,155 | 19.0% |
| 01/01/2021 - 04/01/2021 | 63,773 | 21.8% | 17,210 | 8.6% |

3.2 Hospitalisation

There were 12,714 hospitalisations within 1-14 days in the SGTF group (4.35%) and 6,768 (3.37%) in the non-SGTF group.

3.2.1 Nested case-control analysis

Of the 19,482 hospitalised patients, 18,814 (96.6%) could be matched to a non-hospitalised patient on 5-year age group, sex, ethnicity, region of residence (PHEC), week and IMD quintile. Older age groups were least likely to be matched, with 22.1% not matched in the 85+ group. Most white ethnicity individuals were matched (99.0%), but the proportion was lower for other ethnicities: 95.0% for Asian, 87.0% for Black, 75.5% for mixed, and 85.2% for other. Based on this matched casecontrol analysis, the estimated conditional OR of hospitalisation within 14 days was 1.58 (95% CI 1.50 to 1.67).

When matching on LTLA instead of PHEC, in addition to all other adjustment variables, a matching control was found for 68% of the cases, and the conditional OR was 1.58 (95% CI 1.48 to 1.69).

3.2.2 Stratified cohort analysis

In the stratified cohort analysis, stratification by age group, sex, ethnicity, PHEC, week and IMD quintile resulted in 19,662 covariate combinations, with 379,097 observations (76.9%) used in the conditional logistic regression, giving an OR of 1.55 (95% CI 1.49 to 1.61). Removing variables from the stratification set allowed the use of more observations and gave similar results: without ethnicity, 89% of observations were used with an OR of 1.51 (95% CI 1.45 to 1.57); without IMD, 92% of observations were used with an OR of 1.53 (95% CI 1.48 to 1.60); and without week 94% of observations were used with an OR of 1.47 (95% CI 1.42 to 1.52).

3.2.3 Exploratory cohort analysis

From the logistic regression, the unadjusted OR for SGTF was 1.31 (95% CI 1.27 to 1.35), and the adjusted OR was 1.54 (95% CI 1.49 to 1.60). Adjusting for any single confounder did not substantially alter the unadjusted OR, but adjusting for age, PHEC and specimen date increased the OR for SGTF to 1.51 (95% CI 1.45 to 1.57). Table 2 shows estimated ORs from the full multivariable model. Based on the model, the odds of hospitalisation, adjusted for the other confounders and SGTF status, decreased over the course of the calendar period.

| Covariate | N hospitalised/N (%) | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|--------------------|----------------------|---------------------------|-------------------------|
| SGTF | | (00/00/ | |
| No | 6768/200989 (3.4%) | 1.00 (base) | 1.00 (base) |
| Yes | 12714/292064 (4.4%) | 1.31 (1.27 to 1.35) | 1.54 (1.49 to 1.60) |
| Age | | | |
| <10 | 243/26594 (0.9%) | 0.21 (0.18 to 0.23) | 0.20 (0.18 to 0.23) |
| 10-19 | 444/62945 (0.7%) | 0.16 (0.14 to 0.17) | 0.16 (0.14 to 0.17) |
| 20-29 | 1511/91735 (1.6%) | 0.37 (0.35 to 0.40) | 0.38 (0.35 to 0.40) |
| 30-39 | 2933/96895 (3.0%) | 0.69 (0.66 to 0.73) | 0.69 (0.66 to 0.73) |
| 40-49 | 3748/87184 (4.3%) | 1.00 (base) | 1.00 (base) |
| 50-59 | 4646/74520 (6.2%) | 1.48 (1.42 to 1.55) | 1.55 (1.49 to 1.62) |
| 60-69 | 3151/35189 (9.0%) | 2.19 (2.08 to 2.30) | 2.30 (2.19 to 2.42) |
| 70-79 | 1810/12740 (14.2%) | 3.69 (3.47 to 3.91) | 4.01 (3.77 to 4.26) |
| 80+ | 996/5251 (19.0%) | 5.21 (4.83 to 5.62) | 5.92 (5.48 to 6.39) |
| Sex | | | |
| Female | 9564/256847 (3.7%) | 1.00 (base) | 1.00 (base) |
| Male | 9918/236206 (4.2%) | 1.13 (1.10 to 1.17) | 1.14 (1.11 to 1.18) |
| PHEC Region | | | |
| East Midlands | 927/25324 (3.7%) | 0.89 (0.82 to 0.96) | 1.00 (0.93 to 1.08) |
| East of England | 1963/54236 (3.6%) | 0.88 (0.83 to 0.93) | 0.90 (0.85 to 0.96) |
| London | 4770/120485 (4.0%) | 0.96 (0.92 to 1.01) | 0.90 (0.86 to 0.95) |
| North East | 1295/27029 (4.8%) | 1.18 (1.10 to 1.26) | 1.25 (1.16 to 1.34) |
| North West | 2741/66581 (4.1%) | 1.00 (0.95 to 1.06) | 1.08 (1.03 to 1.15) |
| South East | 3372/82189 (4.1%) | 1.00 (base) | 1.00 (base) |
| South West | 576/14950 (3.9%) | 0.94 (0.86 to 1.02) | 1.00 (0.91 to 1.09) |
| West Midlands | 2400/64691 (3.7%) | 0.90 (0.85 to 0.95) | 0.92 (0.87 to 0.98) |
| Yorkshire & Humber | 1437/37012 (3.9%) | 0.94 (0.89 to 1.01) | 1.04 (0.97 to 1.11) |

Table 2. Estimated odds ratios for hospitalisation within 1-14 days of positive test, from univariable and multivariable logistic regression.

| Ethnicity | | | |
|-------------------------------|---------------------|---------------------|---------------------|
| White | 13646/358595 (3.8%) | 1.00 (base) | 1.00 (base) |
| Asian | 3618/75441 (4.8%) | 1.27 (1.23 to 1.32) | 1.52 (1.46 to 1.58) |
| Black | 855/21010 (4.1%) | 1.07 (1.00 to 1.15) | 1.27 (1.18 to 1.37) |
| Mixed | 322/10834 (3.0%) | 0.77 (0.69 to 0.87) | 1.31 (1.17 to 1.47) |
| Other | 935/19796 (4.7%) | 1.25 (1.17 to 1.34) | 1.54 (1.43 to 1.65) |
| Unknown | 106/7377 (1.4%) | 0.37 (0.30 to 0.45) | 0.42 (0.34 to 0.51) |
| Index of multiple deprivation | | | |
| Quintile 1 – most deprived | 4521/106575 (4.2%) | 1.00 (base) | 1.00 (base) |
| Quintile 2 | 4412/110240 (4.0%) | 0.94 (0.90 to 0.98) | 0.90 (0.87 to 0.95) |
| Quintile 3 | 3824/97395 (3.9%) | 0.92 (0.88 to 0.96) | 0.86 (0.82 to 0.90) |
| Quintile 4 | 3427/91146 (3.8%) | 0.88 (0.84 to 0.92) | 0.80 (0.77 to 0.84) |
| Quintile 5 – least deprived | 3297/87141 (3.8%) | 0.89 (0.85 to 0.93) | 0.80 (0.76 to 0.84) |
| Specimen date | | | |
| 23/11/2020 - 01/12/2020 | 2180/60002 (3.6%) | 1.02 (0.96 to 1.08) | 1.08 (1.02 to 1.15) |
| 02/12/2020 - 08/12/2020 | 1828/49161 (3.7%) | 1.04 (0.98 to 1.11) | 1.09 (1.03 to 1.16) |
| 09/12/2020 - 15/12/2020 | 2818/79037 (3.6%) | 1.00 (base) | 1.00 (base) |
| 16/12/2020 - 22/12/2020 | 2899/76460 (3.8%) | 1.07 (1.01 to 1.12) | 0.97 (0.92 to 1.02) |
| 23/12/2020 - 31/12/2020 | 6430/147410 (4.4%) | 1.23 (1.18 to 1.29) | 0.98 (0.94 to 1.03) |
| 01/01/2021 - 04/01/2021 | 3327/80983 (4.1%) | 1.16 (1.10 to 1.22) | 0.90 (0.85 to 0.94) |

Models including interactions between covariates and SGTF indicated no effect modification according to sex (p=0.845), ethnicity (p=0.727), IMD (p=0.775), or week (p=0.372). There was evidence of a regional effect (p=0.007), with a lower OR for SGTF in London (1.43, 95% CI 1.32 to 1.55) and East of England (OR=1.28, 95% CI 1.14 to 1.44) compared to the OR for other regions (point estimate ranging from 1.53 to 1.75). There was evidence that the effect was modified by age (p<0.001), with little difference in hospitalisation by SGTF status in those under 20 but rising to ORs in the range 1.57 to 1.67 in those aged 40 and older (Table 3).

| Table 3. Age-specific effects of SGTF | from multivariable | logistic regression model. |
|---------------------------------------|--------------------|----------------------------|
|---------------------------------------|--------------------|----------------------------|

| Age group | OR (95% CI) |
|-----------|---------------------|
| <10 | 0.96 (0.74 to 1.24) |
| 10-19 | 1.13 (0.93 to 1.36) |
| 20-29 | 1.22 (1.10 to 1.36) |
| 30-39 | 1.45 (1.33 to 1.57) |
| 40-49 | 1.67 (1.55 to 1.79) |
| 50-59 | 1.65 (1.54 to 1.76) |
| 60-69 | 1.66 (1.53 to 1.80) |
| 70-79 | 1.57 (1.42 to 1.75) |
| 80+ | 1.60 (1.39 to 1.84) |

Based on time-to-event methods, for hospitalisations within 14 days after first positive test, the unadjusted hazard ratio (HR) for SGTF was 1.30 (95% CI 1.26 to 1.34) and the adjusted HR was 1.52 (95% CI 1.46 to 1.57). The Fine and Gray competing risks model provided similar results, with an unadjusted HR of 1.30 (95% CI 1.26 to 1.34) and adjusted HR of 1.52 (95% CI 1.46 to 1.57), within 14 days follow-up. Because the proportion of deaths is low (345 deaths within 14 days, 0.07% of cohort) compared to hospitalisation, the expected impact of deaths as a competing event is small.

Extending the follow-up time to hospital admissions 60 days after first positive test, the unadjusted HR for SGTF was 1.11 (95% CI 1.08 to 1.32) and the adjusted HR was 1.25 (95% CI 1.11 to 1.29). However, the majority of the hospitalisations were in the first 14 days; Appendix Figure A.1 shows cumulative hazards by age group, which show a high hospitalisation rate over the first 14 days and a constant low rate subsequently.

The association between SGTF and hospitalisation varied with time since first positive test, with adjusted HRs of 1.42 (95% CI 1.37 to 1.48) in the first week, 1.53 (95% CI 1.37 to 1.61) in the second week, and with little difference in subsequent weeks (HRs ranging from 0.95 to 1.11).

3.3.4 Matched cohort analysis

Matching by SGTF status instead of hospitalisation resulted in a total of 184,414 SGTF and non-SGTF comparator patients in the matched cohort (37.4%). There were 2,438 admissions (2.52%) among the 92,207 SGTF patients and 1,441 admissions (1.56%) in the 92,207 non-SGTF patients within 1-14 days after the positive specimen. The unadjusted OR of 14-day hospitalisation for SGTF compared to non-SGTF patients was 1.63 (95% CI 1.52 to 1.74). After adjustment, the OR was 1.71 (95% CI 1.60 to 1.82; Appendix Table A.1).

4. Discussion

This retrospective analysis of COVID-19 patients identified through community testing in England indicated that the risk of hospitalisation within 14 days after a positive test was 1.5—1.7 times higher for diagnosed patients infected with the B.1.1.7 variant compared to patients infected with wildtype variants, after matching or stratification for age, sex, deprivation, ethnicity, region and week of diagnosis.

The estimated higher risk of hospitalisation is in line with a previous analysis that estimated a hazard ratio of hospitalisation of 1.34 (95% Cl 1.07 to 1.66), based on follow-up of COVID-19 patients with sequencing-confirmed B.1.1.7 or wildtype SARS-CoV-2 in England [11]. That study observed only 120 hospitalisations in B.1.1.7-infected individuals which yielded a wide confidence interval. By contrast, in the present study we observed 12,714 hospitalisations in patients with SGTF which allowed us to provide higher precision estimates. The results are also consistent with a previous ecological analysis that estimated a hospitalisation relative risk of 1.7 based on hospitalisation patterns by the regional prevalence of SGTF variants in England [9,10], and an analysis that estimated a relative risk of 1.63 based on Scottish data [9].

The results indicated that the higher risk of hospitalisation may be specific to older age groups, and the risk was not found to be higher for SGTF compared to non-SGTF COVID-19 patients below the age of 20. This may reflect a similarly low risk of severe disease in younger and less comorbid individuals as previously reported for wildtype variants [18].

Strengths of this analysis include the use of the community-based dataset, which includes all COVID-19 patients identified through community testing in England. The large dataset allowed for the use of assumption-free methods such as matching or stratification to adjust for confounding due to individual-level demographic and socioeconomic factors, region and calendar period. Although the stratified or matched cohort analyses used a smaller subset of the hospital admissions than the nested case-control analysis, our findings were consistent between the two types of analysis. The calendar period in which the prevalence of the B.1.1.7 increased coincided with a general increase of COVID-19 diagnoses in the UK [19]. The resulting pressure on the healthcare system may have confounded the assessment of mortality outcomes associated with B.1.1.7 in previous studies. Those studies did not directly adjust for hospital over-burden, and only addressed the potential confounder indirectly through adjustment for time period and region [6–8]. In contrast, hospital over-burden is unlikely to positively confound an association between SGTF status and hospital admission, because it is unlikely that higher hospital over-burden results in increased admission rates for diagnosed individuals. On the contrary, our exploratory results suggest that over the study period, after accounting for demographics and SGTF status, there was an overall decrease in the probability that COVID-19 patients were hospitalised. In the absence of this potential confounder in previous analyses, our results corroborate the hypothesis that the B.1.1.7 variant is associated with more severe disease than wildtype variants.

Our study also has limitations. The COVID-19 patients were identified through the Pillar 2 community testing programme, which excludes COVID-19 patients who were diagnosed after presentation directly to emergency or other healthcare services. Individuals who present directly to healthcare services may have more severe disease than those diagnosed through community testing. Community testing is largely self-selected, and we cannot control for the possibility that testing patterns may have differed between individuals infected with the B.1.1.7 variant and individuals infected with wildtype variants. However, some evidence suggests that individuals infected with the B.1.1.7 variant are more likely to experience symptomatic disease compared to other infected individuals [20], but it is unknown if the B.1.1.7 variant is also associated with more severe symptoms in the subset who experience symptoms.

Our analysis is limited by a lack of data on comorbidity and obesity, which are risk factors for hospitalisation among COVID-19 patients [18]. We do not expect that these potential confounders were strongly associated with SGTF status, and they were accounted for indirectly through age, sex, ethnicity and deprivation. In light of the finding that the hospitalisation risk for those infected with the B.1.1.7 variant increased with age, further research is needed to understand whether the severity associated with the B.1.1.7 variant is modified by age, and associated factors such as comorbidity and obesity.

The analysis uses SGTF status which is a proxy test for the B.1.1.7 variant. However, any nondifferential misclassification is likely to result in a small bias towards the null, and the available sequencing data indicate that the positive and negative predictive values of the SGTF test was >90% during the studied period [2].

Reporting delays, particularly for hospitalisation data, might affect this analysis. However, at least 68 days had elapsed between the patients' dates of positive test and the linkage with the hospitalisation data, which makes reporting delays likely to have had limited impact. Furthermore, the SGTF patients were on average diagnosed later than the non-SGTF patients. Hence, any nondifferential underreporting of hospitalisations due to reporting delays may have resulted in underestimation of the hospitalisation risk predominantly in the SGTF patients, which might have resulted in a small underestimation of the true OR. Our analyses controlled for calendar week, which likely makes the effect of this limited. Additionally, the use of hospitalisation data from health service datasets that principally serve administrative purposes has the benefit of broad coverage.

In conclusion, the results from this large nationwide community testing cohort suggest that the risk of hospitalisation is higher for COVID-19 patients infected with the B.1.1.7 variant compared to wildtype variants, likely reflecting that the variant is associated with more severe disease. This higher severity may however be specific to older age groups, and further research is needed to identify if the severity is modified by factors associated with ageing. Taken together with the previous evidence of increased mortality and transmissibility, the results suggest that epidemics of the B.1.1.7 variant are likely to result in higher burden on the healthcare system in unvaccinated populations compared to epidemics of wildtype SARS-CoV-2.

Acknowledgements: We thank Alex Bhattacharya for help with the linkage of the datasets, Paula Blomquist for managing the SGTF data, Mary Sinnathamby for support with the statistical analysis, and Peter Kirwan for helpful suggestions during the manuscript preparation process.

Contributors:

TN, KAT, RJH, SRS, AC, DDA, GD and AMP designed the study.
KAT, RJH, JF, HA, AC and GD contributed to the linkage of the data sources.
RJH and KAT performed the statistical analysis.
TN, KAT, RJH, GD and AMP wrote the manuscript.
SRS, JF, HA, AC and DDA reviewed and revised the manuscript.
AMP, AC and DDA acquired funding.

Competing interests: None.

Funding: This research is funded by the Medical Research Council (TN, DDA, AMP, Unit programme number MC_UU_00002/11, SRS Unit programme number MC_UU_00002/10); and via a grant from the MRC UKRI/DHSC NIHR COVID-19 rapid response call (TN, AC, DDA, AMP, grant ref: MC_PC_19074). This research is also supported by the NIHR Cambridge Biomedical Research Centre.

Role of the funding sources: The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. All authors had full access to all of the data (including statistical reports and tables) in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

References

- [1] pangolin. grinch: global report investigating novel coronavirus haplotypes: B.1.1.7. 2021. https://cov-lineages.org/global_report_B.1.1.7.html (accessed March 30, 2021).
- [2] Public Health England. Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01. 2020. https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201 (accessed March 30, 2021).
- [3] UK Government Prime Minister's Office. Prime Minister announces national lockdown. 2021. https://www.gov.uk/government/news/prime-minister-announces-national-lockdown (accessed March 30, 2021).
- [4] Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 2021. https://doi.org/10.1038/s41586-021-03470-x.
- [5] Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (80-) 2021:eabg3055. https://doi.org/10.1126/science.abg3055.
- [6] Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 2021:n579. https://doi.org/10.1136/bmj.n579.
- [7] Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 2021. https://doi.org/10.1038/s41586-021-03426-1.
- [8] Grint DJ, Wing K, Williamson E, McDonald HI, Bhaskaran K, Evans D, et al. Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Eurosurveillance 2021;26. https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100256.
- [9] NERVTAG. NERVTAG: Update note on B.1.1.7 severity, 11 February 2021. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_d ata/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf (accessed March 30, 2021).
- [10] Abbott S, Funk S. Population-level association between S-gene target failure and the relationship between cases, hospitalisations and deaths of Covid-19. 2021. https://github.com/epiforecasts/covid19.sgene.utla.rt/blob/main/severity-report.pdf.
- [11] Dabrera G, Allen H, Zaidi A, Twohig K, Thelwall S, Marchant E, et al. Assessment of Mortality and Hospital Admissions Associated with Confirmed Infection with SARS-CoV-2 Variant of Concern VOC-202012/01 (B.1.1.7) a Matched Cohort and Time-to-Event Analysis. SSRN Electron J 2021. https://doi.org/10.2139/ssrn.3802578.
- [12] UK Government Department of Health & Social Care. COVID-19 testing data: methodology note. 2020. https://www.gov.uk/government/publications/coronavirus-covid-19-testing-data-methodology/covid-19-testing-data-methodology-note (accessed March 30, 2021).
- [13] NHS Digital. Secondary Uses Service (SUS). 2021. https://digital.nhs.uk/services/secondaryuses-service-sus (accessed March 30, 2021).
- [14] NHS Digital. Emergency Care Data Set (ECDS). 2021. https://digital.nhs.uk/data-andinformation/data-collections-and-data-sets/data-sets/emergency-care-data-set-ecds (accessed March 30, 2021).
- [15] Bhattacharya A, Collin SM, Stimson J, Thelwall S, Nsonwu O, Gerver S, et al. Healthcareassociated COVID-19 in England: a national data linkage study. MedRxiv 2021. https://doi.org/10.1101/2021.02.16.21251625.
- [16] Partlett C, Hall NJ, Leaf A, Juszczak E, Linsell L. Application of the matched nested case-control design to the secondary analysis of trial data. BMC Med Res Methodol 2020;20:117. https://doi.org/10.1186/s12874-020-01007-w.
- [17] Stuart EA. Matching Methods for Causal Inference: A Review and a Look Forward. Stat Sci

2010;25. https://doi.org/10.1214/09-STS313.

- [18] Khawaja AP, Warwick AN, Hysi PG, Kastner A, Dick A, Khaw PT, et al. Associations with covid-19 hospitalisation amongst 406,793 adults: the UK Biobank prospective cohort study. MedRxiv 2020. https://doi.org/10.1101/2020.05.06.20092957.
- [19] Gov.uk. Coronavirus (COVID-19) in the UK. 2021. https://coronavirus.data.gov.uk/ (accessed March 30, 2021).
- [20] Office for National Statistics. Coronavirus (COVID-19) Infection Survey: characteristics of people testing positive for COVID-19 in England, 27 January 2021. 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsan ddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/characteristicsofp eopletestingpositiveforcovid19inengland27january2021#symptoms-profile-by-casescompatible-with-the-new-uk-variant-and-other-positive-cases (accessed March 30, 2021).

Supplementary material for:

Increased risk of hospitalisation for COVID-19 patients infected with SARS-CoV-2 variant B.1.1.7

Tommy Nyberg, research associate ^{a*} Katherine A. Twohig, senior epidemiology scientist ^b Ross J. Harris, senior statistician ^c Shaun R. Seaman, senior research associate ^a Joe Flannagan, senior epidemiology scientist ^b Hester Allen, principal epidemiology scientist ^b Andre Charlett, head of department ^c Daniela De Angelis, professor of statistical science for health ^{a,c} Gavin Dabrera, consultant in public health medicine ^b Anne M. Presanis, senior investigator statistician ^a

^a MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.

^b COVID-19 National Epidemiology Cell, Public Health England, London, United Kingdom.

^c National Infection Service, Public Health England, London, United Kingdom.

* Corresponding author.



Figure A.1: Estimated cumulative hazard curves for hospital admission by days after a first positive test, by 10-year age band.

| | | Unadjusted | | | Adjusted | | | | |
|-----------|------------|------------|-------|-------|----------|-------|-------|-------|--------|
| | | Number | % of | Odds | Lowe | Upper | Odds | Lowe | Upper |
| | | of cases | cases | ratio | r 95% | 95% | Ratio | r 95% | 95% CI |
| | | | | | CI | CI | | CI | |
| SGTF | No | 92,207 | 50.00 | 1.00 | | | 1.00 | | |
| | Yes | 92,207 | 50.00 | 1.63 | 1.52 | 1.74 | 1.71 | 1.60 | 1.82 |
| Sex | Female | 96,282 | 52.21 | 1.00 | | | 1.00 | | |
| | Male | 88,132 | 47.79 | 1.32 | 1.24 | 1.40 | 1.33 | 1.24 | 1.42 |
| Age | <10 | 8,334 | 4.52 | 0.12 | 0.07 | 0.18 | 0.11 | 0.07 | 0.18 |
| | 10-19 | 22,736 | 12.33 | 0.10 | 0.07 | 0.13 | 0.10 | 0.07 | 0.13 |
| | 20-29 | 36,678 | 19.89 | 0.26 | 0.22 | 0.30 | 0.26 | 0.22 | 0.31 |
| | 30-39 | 37,458 | 20.31 | 0.58 | 0.51 | 0.65 | 0.57 | 0.51 | 0.65 |
| | 40-49 | 32,774 | 17.77 | 1.00 | | | 1.00 | | |
| | 50-59 | 28,194 | 15.29 | 1.84 | 1.67 | 2.04 | 1.92 | 1.74 | 2.13 |
| | 60-69 | 13,020 | 7.06 | 3.54 | 3.19 | 3.93 | 3.68 | 3.31 | 4.08 |
| | 70-79 | 4,030 | 2.19 | 6.80 | 6.02 | 7.69 | 7.30 | 6.45 | 8.27 |
| | 80+ | 1,190 | 0.65 | 10.34 | 8.73 | 12.24 | 11.3 | 9.58 | 13.52 |
| | | | | | | | 8 | | |
| Ethnicity | Asian | 29,121 | 15.79 | 1.14 | 1.05 | 1.24 | 1.52 | 1.39 | 1.67 |
| | Black | 7,881 | 4.27 | 0.98 | 0.84 | 1.15 | 1.34 | 1.13 | 1.58 |
| | Mixed | 4,006 | 2.17 | 0.69 | 0.53 | 0.89 | 1.47 | 1.12 | 1.92 |
| | Other | 8,216 | 4.46 | 0.99 | 0.84 | 1.15 | 1.46 | 1.24 | 1.72 |
| | Unknown | 2,710 | 1.47 | 0.38 | 0.25 | 0.57 | 0.47 | 0.31 | 0.72 |
| | White | 132,480 | 71.84 | 1.00 | | | 1.00 | | |
| PHEC | London | 45,132 | 24.47 | 1.00 | | | 1.00 | | |
| | East | 7,526 | 4.08 | 1.51 | 1.29 | 1.77 | 1.60 | 1.35 | 1.88 |
| | Midlands | | | | | | | | |
| | East of | 17,916 | 9.72 | 0.89 | 0.77 | 1.02 | 0.97 | 0.84 | 1.12 |
| | England | | | | | | | | |
| | North East | 14,060 | 7.62 | 1.68 | 1.49 | 1.89 | 1.58 | 1.38 | 1.81 |
| | North | 27,254 | 14.78 | 1.48 | 1.34 | 1.64 | 1.40 | 1.24 | 1.57 |
| | West | | | | | | | | |
| | South East | 25,596 | 13.88 | 1.21 | 1.08 | 1.35 | 1.30 | 1.16 | 1.46 |
| | South | 6,730 | 3.65 | 1.65 | 1.40 | 1.93 | 1.74 | 1.46 | 2.06 |
| | West | | | | | | | | |
| | West | 28,966 | 15.71 | 1.19 | 1.07 | 1.33 | 1.12 | 1.00 | 1.27 |
| | Midlands | 44.224 | 6.00 | | 0.00 | 01.2 | 4.07 | 0.04 | 4.20 |
| | Y&H | 11,234 | 6.09 | 1.11 | 0.96 | 01.3 | 1.07 | 0.91 | 1.26 |
| | QI – most | 40,119 | 21.75 | 1.26 | 1.14 | 1.39 | 1.43 | 1.29 | 1.60 |
| quintile | | 41 070 | 22.22 | 1.07 | 0.07 | 1 10 | 1 2 4 | 1 1 1 | 1 20 |
| | 02 | 41,078 | 22.27 | 1.07 | 0.97 | 1.19 | 1.24 | 1.11 | 1.38 |
| | | 30,811 | 19.90 | 1.03 | 0.93 | 1.15 | 1.12 | 1.00 | 1.25 |
| | | 33,859 | 17.50 | 1.04 | 0.93 | 1.15 | 1.00 | 0.95 | 1.10 |
| | deprived | 32,547 | 17.05 | 1.00 | | | 1.00 | | |

Table A.1: Univariable and multivariable logistic regression estimates for the matched cohort

| Sample | W/c Nov | 10,392 | 5.64 | 1.00 | | | 1.00 | | |
|--------|------------|--------|-------|------|------|------|------|------|------|
| week | 23, 2020 | | | | | | | | |
| | W/c Nov | 16,284 | 8.83 | 0.84 | 0.71 | 1.00 | 0.84 | 0.71 | 1.00 |
| | 30, 2020 | | | | | | | | |
| | W/c Dec 7, | 28,452 | 15.43 | 0.83 | 0.71 | 0.97 | 0.81 | 0.69 | 0.95 |
| | 2020 | | | | | | | | |
| | W/c Dec | 36,726 | 19.91 | 0.86 | 0.74 | 1.00 | 0.75 | 0.64 | 0.87 |
| | 14, 2020 | | | | | | | | |
| | W/c Dec | 43,101 | 23.37 | 1.07 | 0.92 | 1.23 | 0.80 | 0.68 | 0.93 |
| | 21, 2020 | | | | | | | | |
| | W/c Dec | 49,459 | 26.82 | 1.11 | 0.97 | 1.29 | 0.75 | 0.64 | 0.87 |
| | 28, 2020 | | | | | | | | |